What is the 13F Pro Quality Score for PLSE?

13F Pro ranks PULSE BIOSCIENCES, INC. (PLSE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PLSE's current score at https://13fpro.ai/research/PLSE (free sign-up required for the full ranking).

Which hedge funds own the most PLSE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PLSE include BlackRock,, BANK OF AMERICA /DE/, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PLSE as soon as new 13F filings post.

Where does 13F Pro source PLSE data?

All PULSE BIOSCIENCES, INC. fundamentals and ownership data come directly from SEC EDGAR. PULSE BIOSCIENCES, INC. files with the SEC under CIK 1625101. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PLSE in?

PULSE BIOSCIENCES, INC. (PLSE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PLSE research updated on 13F Pro?

PLSE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PULSE BIOSCIENCES, INC.(PLSE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1625101 PLSE stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PLSE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PULSE BIOSCIENCES, INC. (PLSE), a Healthcare sector company. PLSE is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), PULSE BIOSCIENCES, INC. reports quarterly revenue of $401.0K, net income of $-18.6M, free cash flow of $-14.6M. Top institutional holders of PLSE by reported 13-F value include BlackRock,, BANK OF AMERICA /DE/, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PLSE trades on the Nasdaq exchange and files with the SEC under CIK 1625101. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PLSE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PULSE BIOSCIENCES, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$401.0K

Net Income

Q1 2026

$-18.6M

Free Cash Flow

Q1 2026

$-14.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$350.0KFY 2025

FY21 $1.4MFY22 $700.0KFY24 $0.00FY25 $350.0K

Net Income

-35.8% YoY

$-72.8MFY 2025

FY21 $-63.7MFY22 $-58.5MFY24 $-53.6MFY25 $-72.8M

Operating Income

-36.8% YoY

$-76.9MFY 2025

FY21 $-63.0MFY22 $-58.1MFY24 $-56.3MFY25 $-76.9M

Total Assets

-28.6% YoY

$94.5MFY 2025

FY21 $54.2MFY22 $77.9MFY24 $132.5MFY25 $94.5M

Op. Cash Flow

-48.9% YoY

$-54.1MFY 2025

FY21 $-54.1MFY22 $-47.0MFY24 $-36.3MFY25 $-54.1M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2017
Revenue	$350.0K	$0.00 -100.0%	$700.0K -50.6%	$1.4M	$0.00	—
Net Income	$-72.8M -35.8%	$-53.6M +8.4%	$-58.5M +8.1%	$-63.7M -27.7%	$-49.9M -95.0%	$-25.6M
Operating Income	$-76.9M -36.8%	$-56.3M +3.1%	$-58.1M +7.9%	$-63.0M -26.1%	$-50.0M -95.4%	$-25.6M
Total Assets	$94.5M -28.6%	$132.5M +70.1%	$77.9M +43.6%	$54.2M +31.4%	$41.3M -17.1%	$49.8M
Operating Cash Flow	$-54.1M -48.9%	$-36.3M +22.7%	$-47.0M +13.1%	$-54.1M -53.0%	$-35.4M -219.0%	$-11.1M

AI Insight: PLSE Financial Trends

Pre-revenue biotech burning cash consistently with no commercialization progress; equity base declining as losses persist.

• Zero revenue across all eight quarters; operating losses stable at $12M–$20M per quarter with no improvement trajectory.

• Operating cash outflow widened from $8M in Q2 2024 to $15M in Q1 2026, indicating accelerating cash consumption.

• Equity eroded 59% from $118M (Q1 2025 peak) to $66M in Q1 2026, signaling shareholder dilution without offsetting revenue.

⚠ Equity runway at $66M with $15M quarterly burn implies ~4.4 quarters of capital remaining; funding event or revenue inflection critical.

⚠ Operating losses remained flat Q3–Q4 2025 ($19M–$20M), then deteriorated to $19M in Q1 2026 despite no revenue catalysts disclosed.

AI Insight: PLSE Ratio Trends

PLSE's profitability metrics have deteriorated sharply, with ROE declining from -56.7% in Q1 2025 to -112.1% in Q1 2026.

• ROE worsened from -56.7% (Q1 2025) to -112.1% (Q1 2026); ROA fell from -50.4% to -91.1% over same period.

• ROIC deteriorated from -60.9% (Q1 2025) through -90.5% (Q4 2025), signaling consistent operational cash-burn acceleration.

⚠ Q1 2026 ROE/ROA match TTM levels, suggesting losses may have intensified; operating margin data unavailable to assess cash flow trends.

⚠ No leverage or profitability data provided; capital structure and debt sustainability cannot be assessed from available ratios.

Get alerted when PLSE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PULSE BIOSCIENCES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PLSE

BlackRock, Inc.
$28.9M1,339,778 sh
BANK OF AMERICA CORP /DE/
$18.7M866,061 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.6M815,852 sh
Portolan Capital Management, LLC
$15.8M733,372 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.6M491,946 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$10.0M462,899 sh
STATE STREET CORP
$9.9M456,927 sh
BALYASNY ASSET MANAGEMENT L.P.
$5.7M265,164 sh
GRIFFIN ASSET MANAGEMENT, INC.
$4.9M225,177 sh
LMR Partners LLP
$4.6M213,137 sh

Fund	Value	Shares
BlackRock, Inc.	$28.9M	1,339,778
BANK OF AMERICA CORP /DE/	$18.7M	866,061
VANGUARD CAPITAL MANAGEMENT LLC	$17.6M	815,852
Portolan Capital Management, LLC	$15.8M	733,372
GEODE CAPITAL MANAGEMENT, LLC	$10.6M	491,946
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$10.0M	462,899
STATE STREET CORP	$9.9M	456,927
BALYASNY ASSET MANAGEMENT L.P.	$5.7M	265,164
GRIFFIN ASSET MANAGEMENT, INC.	$4.9M	225,177
LMR Partners LLP	$4.6M	213,137

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PLSE on your watchlist

Track score changes the day PULSE BIOSCIENCES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PLSE a good stock to buy?

13F Pro's AI-powered analysis of PULSE BIOSCIENCES, INC. (PLSE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PLSE are available on the PLSE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PLSE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PLSE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PULSE BIOSCIENCES, INC.'s investment landscape.